Business strategy and financing
A biotech company with a nucleic acid-based technology platform and drug pipeline needed to get fresh funds to move their preclinical drug candidates into the clinic.
FHR Consult assumed an interim business development role. We reviewed technology platform, competitors and IP situation and held strategy meetings with all stakeholders. Based on that, a parallel financing strategy was chosen: (i) gearing up for a B round financing and (ii) trying to get non-dilutive funding via early-stage partnerships. In close coordination with the Company, FHR Consult prepared the business plan and partnering strategy, approached potential partners and investors and supported negotiations.
The Company successfully closed a significant financing round which allowed them to start clinical development of their lead programs. In parallel to the VC financing activities, a number of interested collaboration partners were identified. After encouraging clinical results had been obtained, the Company got acquired by a publicly listed company.
Learn more about our services for biotech, pharmaceutical and medtech companies and investors.